Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

The June 9, 2025, FDA approval of clesrovimab (Enflonsia; Merck) marked another advancement for the prevention of respiratory syncytial virus (RSV) disease in infants, especially during their first ...

Global developmental delay (GDD) and intellectual disability (ID) affect an estimated 1% to 3% of children worldwide and are among the most common neurodevelopmental conditions encountered in ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

Among a study population of adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis (AD) and skin of color, dupilumab (Dupixent; Regeneron Pharmaceuticals and Sanofi) ...

Primary care providers may be the first line of defense for children with pediatric acute-onset neuropsychiatric syndrome (PANS), but diagnosing and managing the condition can present significant ...

On June 18, 2025, the FDA approved Gilead Sciences' lenacapavir (Yeztugo), an injectable HIV-1 capsid inhibitor, indicated as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired ...

For pediatricians treating children with atopic dermatitis, safe and effective topical options are now more accessible and increasingly important to understand, says John Browning, MD, chief of ...

Positive, interim data from the phase 2 COACH trial evaluating once-weekly navepegritide (TransCon CNP) and once-weekly lonapegsomatropin (TransCon hGH) combination therapy demonstrated significant ...